RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
April 4, 2018
RegMed Investors’ (RMi) closing bell; relief rally and a rush to the upside
April 3, 2018
RegMed Investors’ (RMi) closing bell; sector flip-flops through-out the session
April 2, 2018
RegMed Investors’ (RMi) closing bell; sector is technically broken
March 29, 2018
RegMed Investors’ (RMi) closing bell; an overdue rally
March 27, 2018
RegMed Investors’ (RMi) closing bell; hammered and an all but a clean sweep of the sector
March 26, 2018
RegMed Investors’ (RMi) closing bell; the sector rallied at open, petered away and came back
March 23, 2018
RegMed Investors’ (RMi) closing bell; swing low, coming for to carry me down
March 21, 2018
RegMed Investors’ (RMi) closing bell; sector regains its footing
March 20, 2018
RegMed Investors’ (RMi) closing bell; the bounce back is small but, happening
March 19, 2018
RegMed Investors’ (RMi) closing bell; markets take a hit as the NASDAQ drags down the sector
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.